Bio-Rad Laboratories (BIO) Cash from Investing Activities Growth (1y) (2010 - 2026)
Bio-Rad Laboratories (BIO) Cash from Investing Activities Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 0.00% |
| 10 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn | 42.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.20% |
| Mar 31, 2026 | -3,313.79% |
| Dec 31, 2025 | -12.13% |
| Sep 30, 2025 | 22.80% |
| Jun 30, 2025 | -273.46% |
| Mar 31, 2025 | 106.73% |
| Dec 31, 2024 | -142.25% |
| Sep 30, 2024 | -486.32% |
| Jun 30, 2024 | -210.42% |
| Mar 31, 2024 | 38.84% |
| Dec 31, 2023 | 223.28% |
| Sep 30, 2023 | 89.26% |
| Jun 30, 2023 | 119.37% |
| Mar 31, 2023 | 92.31% |
| Dec 31, 2022 | 89.68% |
| Sep 30, 2022 | -8.69% |
| Jun 30, 2022 | -44.08% |
| Mar 31, 2022 | -1,795.71% |
| Dec 31, 2021 | -849.53% |
| Sep 30, 2021 | -189.54% |